{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:34:43Z","timestamp":1781886883388,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"am","delay-in-days":316,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ygyno.2022.12.003","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T12:30:12Z","timestamp":1671021012000},"page":"98-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor"],"prefix":"10.1016","volume":"169","author":[{"given":"Diego D.","family":"Manavella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Harold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Max Philipp","family":"Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang-Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Zipponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Demirkiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Skyler","family":"Verzosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Altwerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaagn","family":"Andikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Azodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Dottino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungmin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmil B.","family":"Alexandrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.12.003_bb0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.critrevonc.2014.10.013","article-title":"Rare uterine cancer: carcinosarcomas. Review from histology to treatment","volume":"94","author":"Artioli","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0010","series-title":"Siegel - 2022 - CA: A Cancer Journal for Clinicians","author":"Cancer statistics","year":"2022"},{"key":"10.1016\/j.ygyno.2022.12.003_bb0015","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/IGC.0b013e3181dc8292","article-title":"Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes","volume":"20","author":"Garg","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2022.12.003_bb0020","doi-asserted-by":"crossref","first-page":"12238","DOI":"10.1073\/pnas.1614120113","article-title":"Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition","volume":"113","author":"Zhao","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0025","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.celrep.2012.12.008","article-title":"Deciphering signatures of mutational processes operative in human cancer","volume":"3","author":"Alexandrov","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ygyno.2022.05.005","article-title":"Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor","volume":"166","author":"Tymon-Rosario","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0035","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2022.12.003_bb0040","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0045","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models","volume":"63","author":"L\u00fccking","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical Cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2022.12.003_bb0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ijgo.12614","article-title":"Cancer of the ovary, fallopian tube, and peritoneum","volume":"143","author":"Berek","year":"2018","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/GRF.0b013e3182185baa","article-title":"Revised FIGO staging system for endometrial cancer","volume":"54","author":"Lewin","year":"2011","journal-title":"Clin. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0065","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025182118","article-title":"Integrated mutational landscape analysis of uterine leiomyosarcomas","volume":"118","author":"Choi","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0070","first-page":"517","article-title":"Cancer genome atlas research network, Prognostically relevant gene signatures of high-grade serous ovarian carcinoma","volume":"123","author":"Verhaak","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0075","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1126\/science.1140735","article-title":"An oncogene-induced DNA damage model for cancer development","volume":"319","author":"Halazonetis","year":"2008","journal-title":"Science."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0080","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0085","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/ncb1337","article-title":"ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks","volume":"8","author":"Jazayeri","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0090","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","article-title":"Chk1 is an essential kinase that is regulated by Atr and required for the G(2)\/M DNA damage checkpoint","volume":"14","author":"Liu","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0095","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in Cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ygyno.2022.12.003_bb0100","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the Oral Ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0105","series-title":"Presented at: 2022 AACR Annual Meeting; April 8\u201313, 2022; New Orleans, Louisiana. Abstract CT006","article-title":"Phase 1b expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related inhibitor elimusertib in advanced solid tumors with DNA damage response defects","author":"Yap","year":"2022"},{"key":"10.1016\/j.ygyno.2022.12.003_bb0110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0115","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2022.12.003_bb0120","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1038\/onc.2014.276","article-title":"ATR inhibition preferentially targets homologous recombination-deficient tumor cells","volume":"34","author":"Krajewska","year":"2015","journal-title":"Oncogene."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0125","doi-asserted-by":"crossref","first-page":"13837","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0130","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0135","doi-asserted-by":"crossref","first-page":"7734","DOI":"10.1093\/nar\/gkz634","article-title":"DAXX in cancer: phenomena, processes, mechanisms and regulation","volume":"47","author":"Mahmud","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0140","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026567","article-title":"ATRX and DAXX: mechanisms and mutations","volume":"7","author":"Dyer","year":"2017","journal-title":"Cold Spring Harb Perspect Med."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0145","doi-asserted-by":"crossref","first-page":"13620","DOI":"10.1074\/jbc.M112.446369","article-title":"Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance","volume":"288","author":"Pan","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0150","series-title":"Elimusertib (BAY1895344), a Novel ATR Inhibitor, Demonstrates In Vivo Activity in ATRX Mutated Models of Uterine Leiomyosarcoma, Gynecologic Oncology. Submitted","author":"Harold","year":"2022"},{"key":"10.1016\/j.ygyno.2022.12.003_bb0155","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/modpathol.2011.88","article-title":"Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component","volume":"24","author":"de Jong","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0160","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.humpath.2008.01.003","article-title":"Cheryl Brown ovarian Cancer outcomes unit of the British Columbia Cancer Agency, tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma","volume":"39","author":"Gilks","year":"2008","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2022.12.003_bb0165","first-page":"3","article-title":"Tumor grade and chemotherapy response in endometrioid endometrial cancer, Gynecol","volume":"17","author":"Davidson","year":"2016","journal-title":"Oncol. Rep."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822019825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822019825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:03:36Z","timestamp":1758773016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822019825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":33,"alternative-id":["S0090825822019825"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.12.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}